Skip to main content

C-RAD AB: Three systems to Italy

Press release 2011-12-12

Press release 2011-12-12


Orders of three systems to Italy

C-RAD AB with its four fully owned subsidiaries are all active in the field of radiation therapy. The C-RAD representative Radius s.r.l. in Italy has placed orders of three systems.

With the introduction of the Catalyst™ system C-RAD has launched a unique solution for use in advanced radiation therapy. The Sentinel™ system is as a standard equipped with functionality for motion control of the patient during the treatment. Functionality for 4DCT and positioning can be added.

The new Catalyst™ system and the previously launched Sentinel™ system form a complete product offering and tailored configurations can be offered based on customer requests. With this product portfolio is C-RAD the world leading company to offer optical surface tracking and monitoring systems for enhanced precision, patient safety and efficiency in advanced radiation therapy.

The ordered systems will be delivered to three different sites in Italy. The first one, will be a Sentinel system for patient set up and motion detection during treatment with linear accelerator; the second delivery will be fully equipped with functionalities for respiratory gating, motion detection and positioning of the patient. The Catalyst system will be interfaced to an accelerator system. The Sentinel will be installed at a CT scanner dedicated to radiotherapy treatment simulations. The third delivery will be a Sentinel system equipped with functionality for 4DCT interfaced to a CT scanner dedicated to radiotherapy treatment simulations.

Erik Hedlund, CEO, C-RAD AB:

"Italy has for C-RAD become one of the major markets in Europe. The result is based on excellent and long term cooperation between the two companies Radius and C-RAD. Clinical reports has been published and are being used in the worldwide marketing of the Sentinel system. "

Mauro Mei, CEO, Radius s.r.l.:

“Every successful business story requires a certain number of genuine ingredients, like, for instance, the preparation of a good Mediterranean cuisine dish. In our case, the genuine ingredients are:

  • Long term relationship and reciprocal respect among each person (technical and commercial) of both companies
  • Constant focus on the clinical improvements in radiotherapy, full commitment to patient treatment efficacy and safety “

The products of C-RAD are perfectly fitting into Radius’ portfolio for Radiotherapy, dedicated to excellence, with state-of-the-art products, like proton therapy, adaptive therapy and IGRT. The common goal is to improve the efficiency of treatment, reducing as much as possible every kind of side effect.


For further information:

Erik Hedlund, CEO C-RAD AB, Phone +46-(0)18-66 69 31, E-Mail


Close Menu